Evidence map›Paper›PMID 42177749›Full record

ArticleDigestive diseases and sciences2026

Healthcare Providers' Perspectives on the Role of Artificial Intelligence in the Care of Patients with Inflammatory Bowel Disease: An International Survey.

Jalpa Devi, Colleen Y Colbert, Sophia Haroon Dar, Beatriz Gros, Ashkan Rezazadeh Ardabili, Agnes H Y Ho, Anita D Misra-Hebert, Joseph Sleiman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jalpa DeviDivision of Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, NE, USA.
Colleen Y ColbertCleveland Clinic Education Foundation, Cleveland Clinic, Cleveland, OH, USA.
Sophia Haroon DarDivision of Gastroenterology, Southern Illinois University School of Medicine, Springfield, IL, USA.
Beatriz GrosReina Sofia University Hospital, IMIBIC, University of Cordoba, Cordoba, Spain.
Ashkan Rezazadeh ArdabiliDepartment of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands.
Agnes H Y HoDivision of Gastroenterology and Hepatology, Faculty of Medicine and Therapeutics, The Chinese University of Hong Kong, Ma Liu Shui, Hong Kong.
Anita D Misra-HebertCleveland Clinic Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Joseph SleimanDigestive Disease Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA. sleimaj4@ccf.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundArtificial intelligence (AI) is transforming inflammatory bowel disease (IBD) care, but concerns over data quality, privacy, and provider familiarity remain.

aimsTo examine international health care providers' (HCPs) perceptions, clinical use of, and barriers to applying AI in IBD care.

methodsAn anonymous 17-item survey was developed and pretested by an international team. The survey was fielded internationally from January to May 2025 via social media, international IBD newsletters and email listservs.

resultsOf 323 IBD professionals from North America (35.3%), Europe (26.0%), Asia-Pacific (19.2%), 207 (64.1%) viewed AI as very or extremely promising. AI-assisted endoscopy was reportedly adopted by 131 (40.6%) of respondents, but only 69 (21.4%) reported applying AI in IBD care or research. Males supported AI in IBD endoscopic scoring (89.9% vs. 79.1%, p = 0.009) and radiomics more than females (86.6% vs. 75.2%, p = 0.022), while females endorsed AI for patient education more than males (81.5% vs. 70.6%, p = 0.026). 145 (44.9%) respondents were concerned about AI usage in IBD care. Females were less concerned about cost (18.5% vs. 30.1%, p = 0.019) and more concerned about oversight (28.7% vs. 14.7%, p = 0.003). Concerns regarding AI usage decreased with age (OR 0.021 for age > 55 compared to age 25-34 years old; 95% CI 0.13-0.84). Exposure to IBD-focused AI-based tools was associated with more favorable perceptions of AI use in IBD care (OR 2.63, 95% CI 1.25-5.53).

conclusionBased upon survey results, HCPs had concerns over insufficient education, regulatory ambiguity, and perplexing implementation strategies for AI. Proven clinical benefit (74.9%) and adequate AI training (72.1%) are the top solutions for enabling the appropriate adoption of AI tools in IBD.

Indexed as

Artificial IntelligenceAttitude of Health PersonnelHealth PersonnelInflammatory Bowel DiseasesAdultFemaleHumansMaleMiddle AgedSurveys and QuestionnairesAI implementationArtificial intelligenceEndoscopyHealth personnelIBDInflammatory bowel diseases

Identifiers

PMID42177749
PMCPMC13558307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.